Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Iversen

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
American Journal of Human Genetics|July 14, 2001
A genomewide screen for autism susceptibility lociJ Liu, D R Nyholt, P Magnussen, et al.
Clinical Drug Investigation|January 24, 2013
Management options for gynaecomastia and breast pain associated with nonsteroidal antiandrogen therapy : case report seriesI Leibovitch, D Gillatt, P Hopwood, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1996
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized ratsM Sato, H U Bryant, P Iversen, et al.
Scandinavian Journal of Urology|February 23, 2016
Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization studyT M Kjærulff, A K Ersbøll, A Green, et al.
Urology|March 24, 1998
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 yearsP Iversen, C J Tyrrell, A V Kaisary, et al.
Photochemistry and Photobiology|October 25, 2000
Photoactivation of vascular iNOS and elevation of cGMP in vivo: possible mechanism for photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit modelsN Kipshidze, M H Keelan, J R Petersen, et al.
Multiple Sclerosis and Related Disorders|January 12, 2018
Disability in progressive MS is associated with T2 lesion changesC Ammitzbøll, T B Dyrby, M Lyksborg, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 9, 2001
Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury modelN Kipshidze, E Keane, D Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
European Urology|September 18, 2002
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6P Iversen, T L J Tammela, S Vaage, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
American Journal of Human Genetics|July 14, 2001
A genomewide screen for autism susceptibility lociJ Liu, D R Nyholt, P Magnussen, et al.
Clinical Drug Investigation|January 24, 2013
Management options for gynaecomastia and breast pain associated with nonsteroidal antiandrogen therapy : case report seriesI Leibovitch, D Gillatt, P Hopwood, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1996
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized ratsM Sato, H U Bryant, P Iversen, et al.
Scandinavian Journal of Urology|February 23, 2016
Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization studyT M Kjærulff, A K Ersbøll, A Green, et al.
Urology|March 24, 1998
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 yearsP Iversen, C J Tyrrell, A V Kaisary, et al.
Photochemistry and Photobiology|October 25, 2000
Photoactivation of vascular iNOS and elevation of cGMP in vivo: possible mechanism for photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit modelsN Kipshidze, M H Keelan, J R Petersen, et al.
Multiple Sclerosis and Related Disorders|January 12, 2018
Disability in progressive MS is associated with T2 lesion changesC Ammitzbøll, T B Dyrby, M Lyksborg, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 9, 2001
Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury modelN Kipshidze, E Keane, D Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
European Urology|September 18, 2002
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6P Iversen, T L J Tammela, S Vaage, et al.
Pageof 15